Arbutus Biopharma Cp (ABUS) Stock Price, Quote & News

Company Profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the poten...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 469 0914

Website: www.arbutusbio.com

Address:

701 Veterans Circle, Warminster, United States

SpaceCityKid Sep. 9 at 3:16 PM

$ABUS ROIV testing ATH. Moment of truth

0 · Reply

NakdEnergy Sep. 9 at 3:07 PM

$ABUS Any thoughts on why we aren’t getting a decision on the Pfizer Markman? Seems a little more than unusual for this to o be taking so long?

1 · Reply

DocPharm Sep. 9 at 2:29 PM

$ROIV ATH incoming🥳🎉; $ABUS to follow shortly IMO

1 · Reply

Thecheese12 Sep. 9 at 2:17 PM

$ABUS tick tock moderna. Everyday is costing your investors millions.

0 · Reply

DocPharm Sep. 9 at 2:11 PM

$ABUS

0 · Reply

SpaceCityKid Sep. 9 at 1:47 PM

$ABUS Selling already drying up.

0 · Reply

StockosaurusTex Sep. 9 at 1:46 PM

$ABUS investor relations

0 · Reply

PsiXPsi Sep. 9 at 1:27 PM

$ABUS anyone have the schedule for upcoming trial dates? I think it was posted a bit ago, but can’t seem to find it.

1 · Reply

DocPharm Sep. 8 at 8:08 PM

$ABUS Thinking around Thursday should run

2 · Reply

LM_Johanssen Sep. 8 at 7:23 PM

$ABUS Last Monday wasn’t so great for the stock either, but the rest of the week turned out alright.

1 · Reply

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 25, 2025, 7:30 AM EDT - 2 months ago

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

May 14, 2025, 7:30 AM EDT - 4 months ago

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 7, 2025, 2:01 AM EDT - 4 months ago

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Apr 23, 2025, 2:01 AM EDT - 4 months ago

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Mar 27, 2025, 7:56 AM EDT - 5 months ago

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Mar 27, 2025, 7:30 AM EDT - 5 months ago

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Mar 3, 2025, 9:15 AM EST - 6 months ago

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ROIV

Feb 25, 2025, 7:00 AM EST - 7 months ago

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Jan 30, 2025, 3:40 PM EST - 7 months ago

Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.

BUR CDZI

Jan 13, 2025, 7:30 AM EST - 8 months ago

Arbutus Provides 2025 Corporate and Financial Update

Jan 7, 2025, 7:56 AM EST - 8 months ago

Arbutus: Positive Imdusiran Data Leads To Phase 2B Development

Dec 3, 2024, 8:00 AM EST - 10 months ago

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Nov 26, 2024, 7:30 AM EST - 10 months ago

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Nov 15, 2024, 11:02 AM EST - 10 months ago

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Nov 14, 2024, 7:30 AM EST - 10 months ago

Arbutus to Present at Jefferies London Healthcare Conference

Nov 6, 2024, 2:52 PM EST - 10 months ago

Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript

Oct 23, 2024, 7:30 AM EDT - 11 months ago

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Oct 15, 2024, 8:16 AM EDT - 11 months ago

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Participate in Two Upcoming Investor Conferences

Aug 1, 2024, 2:00 PM EDT - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 18, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Jul 5, 2024, 5:29 AM EDT - 1 year ago

Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity

Jun 6, 2024, 11:15 AM EDT - 1 year ago

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Jun 5, 2024, 2:30 AM EDT - 1 year ago

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Jun 3, 2024, 9:50 AM EDT - 1 year ago

Arbutus Distributors Ltd. News Release

May 29, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Participate in Jefferies Global Healthcare Conference

May 22, 2024, 2:00 AM EDT - 1 year ago

Arbutus to Present Imdusiran Data at EASL Congress 2024

May 17, 2024, 9:00 AM EDT - 1 year ago

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

May 2, 2024, 1:15 PM EDT - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Call Transcript

May 2, 2024, 7:30 AM EDT - 1 year ago

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 7:25 AM EDT - 1 year ago

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

Apr 18, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Apr 4, 2024, 8:30 AM EDT - 1 year ago

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Feb 29, 2024, 1:05 PM EST - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 7:30 AM EST - 1 year ago

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Feb 15, 2024, 7:30 AM EST - 1 year ago

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Jan 8, 2024, 7:30 AM EST - 1 year ago

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Nov 9, 2023, 4:01 PM EST - 1 year ago

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Nov 7, 2023, 11:06 AM EST - 2 years ago

Arbutus Biopharma Corporation (ABUS) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 7:30 AM EST - 2 years ago

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 7:15 AM EST - 2 years ago

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

Oct 24, 2023, 7:30 AM EDT - 2 years ago

Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Oct 18, 2023, 7:30 AM EDT - 2 years ago

Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference

Oct 11, 2023, 8:05 AM EDT - 2 years ago

Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023

Sep 11, 2023, 4:15 PM EDT - 2 years ago

Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended

Aug 3, 2023, 7:30 AM EDT - 2 years ago

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update

Jul 20, 2023, 7:30 AM EDT - 2 years ago

Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update

Jul 12, 2023, 7:30 AM EDT - 2 years ago

Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors

SpaceCityKid Sep. 9 at 3:16 PM

$ABUS ROIV testing ATH. Moment of truth

0 · Reply

NakdEnergy Sep. 9 at 3:07 PM

$ABUS Any thoughts on why we aren’t getting a decision on the Pfizer Markman? Seems a little more than unusual for this to o be taking so long?

1 · Reply

DocPharm Sep. 9 at 2:29 PM

$ROIV ATH incoming🥳🎉; $ABUS to follow shortly IMO

1 · Reply

Thecheese12 Sep. 9 at 2:17 PM

$ABUS tick tock moderna. Everyday is costing your investors millions.

0 · Reply

DocPharm Sep. 9 at 2:11 PM

$ABUS

0 · Reply

SpaceCityKid Sep. 9 at 1:47 PM

$ABUS Selling already drying up.

0 · Reply

StockosaurusTex Sep. 9 at 1:46 PM

$ABUS investor relations

0 · Reply

PsiXPsi Sep. 9 at 1:27 PM

$ABUS anyone have the schedule for upcoming trial dates? I think it was posted a bit ago, but can’t seem to find it.

1 · Reply

DocPharm Sep. 8 at 8:08 PM

$ABUS Thinking around Thursday should run

2 · Reply

LM_Johanssen Sep. 8 at 7:23 PM

$ABUS Last Monday wasn’t so great for the stock either, but the rest of the week turned out alright.

1 · Reply

Nile1 Sep. 8 at 6:13 PM

$ABUS $ABUS red to green move is coming, buckle up

0 · Reply

SpaceCityKid Sep. 8 at 5:14 PM

$ABUS ROIV nice recovery from early light vol sell-off. ABUS will follow

2 · Reply

fivehundredpercent Sep. 8 at 4:35 PM

$ABUS its also a potential treasury candidate like $OCTO $FORD $BMNR etc

2 · Reply

DocPharm Sep. 8 at 3:17 PM

$ABUS Mostly MM to MM, shakin’ the basket Volume dries up every time we retreat… No new faces really, yet… Likely few retail sellers here

1 · Reply

MagaDaddy Sep. 8 at 2:30 PM

$ABUS Added…AGAIN We got Moderna and Pfizer by the balls and squeezing!

1 · Reply

Tarheel_Trader Sep. 8 at 2:27 PM

$ABUS wheres my volume today ?

1 · Reply

Blueviking Sep. 8 at 1:30 PM

$ABUS All you got to do here, is just WAIT for IT🥳🚀

0 · Reply

J_Wayne Sep. 8 at 12:37 PM

$ABUS

0 · Reply

StockosaurusTex Sep. 8 at 12:15 PM

$ABUS

0 · Reply

JB6791 Sep. 8 at 12:08 PM

$ABUS MooMoo showing 4.27 Robinscmuck showing 4.03 lol

0 · Reply

jaspershe Sep. 8 at 11:40 AM

$ABUS the one stock that is good news in my life is ABUS. After surviving a 70%drop, we are back baby. Don’t let me down.

1 · Reply

DaxCo Sep. 7 at 7:28 PM

$ABUS did the Russians also steel our patent ? 🤔

1 · Reply

Market Cap	592.57M
Revenue (ttm)	18.14M
Net Income (ttm)	-72.85M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	649,900
Avg Vol	936,122
Day's Range	N/A - N/A
Shares Out	188.72M
Stochastic %K	2%
Beta	1.98
Analysts	Strong Sell
Price Target	$4.50